Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site.

Pro Medicus (ASX:PME) FY21 result: Buy/hold/sell?

Pro Medicus Limited (ASX: PME) is the ASX share I wish I owned. After the latest FY21 result, what's the verdict on its shares?

Pro Medicus Limited (ASX: PME) is the ASX share I wish I owned.

On Wednesday, the company released FY21 results which sent its shares up over 15% by the end of the day.

Taking a step further back, however, it’s easy to see why Pro Medicus has been under the spotlight recently. Long-term holders have been handsomely rewarded for their patience – earning more than a 10 bagger over the past four years.

Source: Rask Media PME 5-year share price chart

For a detailed breakdown of its recent results, you can read my colleague, Jaz Harrison’s article here: FY21 result: Is Pro Medicus (ASX: PME) the best ASX share?

Pro Medicus results recap

Pro Medicus reported a 19.5% jump in revenue to $67.9 million. Like other software companies with high amounts of operating leverage, it was able to grow underlying net profit after tax by 41% to $42.6 million.

Excluding the effects of foreign exchange (FX) movements, this number becomes a 56.3% increase.

Pro Medicus scaled back a lot of its advertising and conferencing costs as a result of COVID-19, which partly explains why it reported an astronomical FY21 EBIT margin of more than 63% (53% in FY20).

It’s likely that this margin will compress slightly in future years as spending normalises with the recovery of the pandemic.

What to do with Pro Medicus shares?

There’s not too much disagreement about the quality of Pro Medicus as a company.

Instead, most concerns surround its current valuation. This is also a crucial factor that will impact the level of returns you, as a shareholder, can ultimately generate.

At the current share price, the market has collectively valued its shares at over 100x Pro Medicus’ latest revenue figure, or over 190x its latest underlying earnings.

I don’t doubt that the company can continue to win new contracts and move into other areas like AI and cloud competence. But, it’s worth considering how much of this growth is baked into the current share price.

Great company, not so great valuation. If the latter improves, I’d love to become a shareholder of Pro Medicus at some point. For now, they’re a hold in my book.

Did you miss out on Pro Medicus like I did? I’d highly recommend signing up for free Rask account and accessing our full stock reports. Click this link to join for free and access all of our free analyst reports.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content